Impact of NEOD001 on Neuropathy in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction: Results From the Expansion Phase of a Phase 1/2 Study

被引：0
|
作者：
Liedtke, Michaela [1 ]
Comenzo, Raymond L. [2 ]
Landau, Heather [3 ]
Sanchorawala, Vaishali [4 ]
Weiss, Brendan M. [5 ]
Zonder, Jeffrey [6 ]
Walling, Jackie [7 ]
Kinney, Gene G. [8 ]
Koller, Martin [8 ]
Schenk, Dale B. [8 ]
Guthrie, Spencer D. [8 ]
Liu, Enchi [8 ]
Gertz, Morie A. [9 ]
机构：
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[2] Tufts Med Ctr, Boston, MA 02111 USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Boston Univ, Sch Med, Boston, MA 02118 USA
[5] Univ Penn, Philadelphia, PA 19104 USA
[6] Karmanos Canc Inst, Detroit, MI USA
[7] JW Consulting, Hillsborough, CA USA
[8] Prothena Biosci Inc, San Francisco, CA USA
[9] Mayo Clin, Rochester, MN USA
来源：
NEUROLOGY | 2017年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S5.001
引用
收藏
页数：3
相关论文
共 50 条
  • [21] The PRONTO amyloidosis study: A randomized, double-blind, placebo-controlled, global, phase 2b study of NEOD001 in previously treated subjects with light chain amyloidosis and persistent cardiac dysfunction.
    Merlini, Giampaolo
    Liedtke, Michaela
    Landau, Heather Jolie
    Comenzo, Raymond L.
    Sanchorawala, Vaishali
    Weiss, Brendan M.
    Zonder, Jeffrey A.
    Schonland, Stefan
    Guthrie, Spencer D.
    Walling, Jackie
    Kinney, Gene G.
    Koller, Martin
    Gertz, Morie A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Rain (Renal AL Amyloid Involvement And NEOD001): A Multicenter, Randomized, Phase 2b Study of NEOD001 in Previously Treated Subjects With Systemic AL Amyloidosis and Persistent Renal Involvement
    Varga, Cindy
    Dispenzieri, Angela
    Gertz, Morie A.
    Goodman, Stacey A.
    Hsu, Kristen
    Inker, Leslie
    Landau, Heather
    Leung, Nelson
    Mikhael, Joseph R.
    Sher, Taimur
    Weiss, Brendan M.
    Wong, Sandy W.
    Zonder, Jeffrey A.
    Comenzo, Raymond L.
    BLOOD, 2017, 130
  • [23] Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients
    Gertz, Morie A.
    Cohen, Adam D.
    Comenzo, Raymond L.
    Du Mond, Charles
    Kastritis, Eftathios
    Landau, Heather J.
    Libby, Edward N., III
    Liedtke, Michaela
    Merlini, Giampaolo
    Sanchorawala, Vaishali
    Schoenland, Stefan O.
    Wechalekar, Ashutosh D.
    Zonder, Jeffrey A.
    Kinney, Gene
    BLOOD, 2019, 134
  • [24] The VITAL Amyloidosis Study: A Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study of NEOD001 in Patients with AL Amyloidosis and Cardiac Dysfunction
    Liedtke, Michaela
    Merlini, Giampaolo
    Landau, Heather
    Comenzo, Raymond L.
    Sanchorawala, Vaishali
    Weiss, Brendan M.
    Zonder, Jeffrey A.
    Walling, Jackie
    Kinney, Gene G.
    Koller, Martin
    Gertz, Morie A.
    BLOOD, 2016, 128 (22)
  • [25] PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS TREATED WITH NEOD001 ACHIEVE RAPID ORGAN RESPONSES THAT ARE INDEPENDENT OF PREVIOUS PLASMA CELL-DIRECTED THERAPIES
    Gertz, M. A.
    Comenzo, R. L.
    Landau, H.
    Sanchorawala, V.
    Weiss, B. M.
    Zonder, J. A.
    Walling, J.
    Kinney, G. G.
    Koller, M.
    Schenk, D. B.
    Guthrie, S. D.
    Liu, E.
    Liedtke, M.
    HAEMATOLOGICA, 2017, 102 : 3 - 3
  • [26] The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction.
    Liedtke, Michaela
    Merlini, Giampaolo
    Landau, Heather Jolie
    Comenzo, Ray
    Seldin, David C.
    Weiss, Brendan M.
    Zonder, Jeffrey A.
    Walling, Jackie
    Kinney, Gene
    Koller, Marty
    Gertz, Morie A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] NEOD001 Specifically Binds Aggregated Light Chain Infiltrates in Multiple Organs from Patients with AL Amyloidosis and Promotes Phagocytic Clearance of AL Aggregates in Vitro
    Zago, Wagner
    Renz, Mark
    Torres, Ronald
    Dolan, Philip J.
    Barbour, Robin M.
    Salmans, Joshua R.
    Shughrue, Paul J.
    Schenk, Dale
    Kinney, Gene C.
    BLOOD, 2015, 126 (23)
  • [28] Pomalidomide and Dexamethasone in Patients with Relapsed AL (Light Chain) Amyloidosis: Results of a Phase 1 Study
    Sanchorawala, Vaishali
    Shelton, Anthony C.
    Lo, Stephen
    Sloan, John Mark
    Seldin, David C.
    BLOOD, 2014, 124 (21)
  • [29] OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis
    Palladini, Giovanni
    Schonland, Stefan O.
    Lentzsch, Suzanne
    Cibeira, M. Teresa
    Hajek, Roman
    Jaccard, Arnaud
    Jamroziak, Krzysztof
    Kastritis, Eftathios
    Sanchorawala, Vaishali
    Schjesvold, Fredrik H.
    Wechalekar, Ashutosh D.
    Thuresson, Sara
    Harmenberg, Johan
    Byrne, Catriona
    Merlini, Giampaolo
    BLOOD, 2019, 134
  • [30] OP201: A phase 1/2 study of melflufen and dexamethasone in patients with immunoglobulin light chain (AL) amyloidosis
    Schoenland, S.
    Palladini, G.
    Lentzsch, S.
    Cibeira, M. T.
    Hajek, R.
    Jaccard, A.
    Jamroziak, K.
    Kastritis, E.
    Sanchorawala, V
    Schjesvold, F. H.
    Wechalekar, A.
    Thuresson, S.
    Harmenberg, J.
    Byrne, C.
    Merlini, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 182 - 182
12345